Table 1 Case reports included in the final analysis.
Author | Country | N = 64 | Malignancy | Age (years) | Gender | Liver histology | Platelets (n°/mm3) | Total bilirubin (mg/dl) | Albumin (g/dl) | Chemotherapy |
|---|---|---|---|---|---|---|---|---|---|---|
Adler et al.33 | UK | 1 | Breast | 63 | F | Breast cancer cells | 198.000 | 2.92 | 3.5 | Yes |
Battisti et al.34 | Italy | 1 | Colon | 69 | M | n.a. | n.a. | n.a. | n.a. | Yes |
Borja et al.35 | US | 1 | Breast | 46 | F | Breast cancer cells; fibrosis | 225.000 | 6.8 | 2.7 | Yes |
Busni et al.2 | US | 1 | Breast | 37 | F | Breast cancer cells; fibrosis | n.a. | n.a. | n.a. | No |
Cerny et al.36 | Czech Republic | 1 | Breast | 68 | F | Breast cancer cells; fibrosis | n.a. | n.a. | n.a. | Yes |
Cervoni et al.37 | France | 1 | Breast | 52 | F | Breast cancer cells; fibrosis | n.a. | 2.92 | n.a. | Yes |
Chandrakan et al.38 | US | 1 | Breast | 45 | F | Breast cancer cells; fibrosis | n.a. | n.a. | n.a. | Yes |
Chin et al.39 | n.a. | 1 | Stomach | 63 | n.a. | n.a. | n.a. | n.a. | n.a. | Yes |
Deprez et al.40 | Belgium | 1 | Breast | 59 | F | Breast cancer cells; fibrosis | n.a. | n.a. | n.a. | Yes |
Eidenschink et al.41 | US | 1 | Breast | 83 | F | Breast cancer cells | n.a. | 7.9 | 2.6 | No |
Finocchi et al.42 | Italy | 1 | Breast | 46 | F | Breast cancer cells; fibrosis | n.a. | 3.3 | 2.6 | No |
Fournier et al.43 | US | 1 | Breast | 52 | F | Breast cancer cells | 50.000 | 17 | n.a. | Yes |
Graber et al.3 | France | 1 | Breast | 57 | F | Breast cancer cells; fibrosis | 70.000 | 3.45 | n.a. | No |
Harry et al.44 | US | 1 | Thyroid | 49 | F | Medullary thyroid cancer cells; fibrosis | n.a. | n.a. | 3.1 | Yes |
Hidalgo-Blanco et al.45 | Spain | 1 | Breast | 39 | F | Breast cancer cells | n.a. | n.a. | n.a. | Yes |
Honma et al.46 | Japan | 1 | Breast | 48 | F | Breast cancer cells; fibrosis | n.a. | n.a. | n.a. | Yes |
Jungst et al.47 | Germany | 1 | Breast | 70 | F | Breast cancer cells; fibrosis | 98.000 | 3.5 | 1.8 | n.a. |
Kang et al.22 | US | 1 | Pancreas | 55 | F | n.a. | n.a. | 1.54 | 1.7 | Yes |
Kashyap et al.48 | India | 1 | Breast | 35 | F | n.a. | n.a. | n.a. | n.a. | Yes |
Kears et al.49 | n.a. | 1 | Breast | 43 | F | n.a. | n.a. | n.a. | n.a. | n.a. |
Klinge et al.6 | Germany | 1 | Breast | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. |
Kobashigawa et al.50 | Japan | 1 | Esophagus | 68 | M | n.a. | n.a. | n.a. | n.a. | Yes |
Lee et al.8 | Korea | 1 | Breast | 47 | F | Breast cancer cells | n.a. | n.a. | n.a. | Yes |
Leyden et al.51 | Ireland | 1 | Breast | n.a. | F | Breast cancer cells | 95.000 | 2.87 | 3 | n.a. |
Liu et al.52 | Taiwan | 1 | Breast | 44 | F | n.a. | n.a. | 11.8 | n.a. | Yes |
Marzuk et al.53 | US | 1 | Breast | 63 | F | Breast cancer cells | 121.000 | 1.45 | 2.5 | Yes |
Maynard et al.54 | US | 1 | Breast | 52 | F | Breast cancer cells; fibrosis | n.a. | 5.2 | 2.4 | no |
Mitani et al.55 | Japan | 1 | Stomach | 74 | M | Adenocarcinoma | n.a. | 2.8 | 1.8 | Yes |
Nakajima et al.56 | Japan | 1 | Breast | 68 | F | Breast cancer cells; fibrosis | 93.000 | 4.97 | 3.1 | Yes |
Ojeda et al.57 | n.a. | 1 | Lung | n.a. | n.a. | Oat cell bronchial carcinoma | n.a. | n.a. | n.a. | n.a. |
Patel et al.58 | US | 1 | Breast | 80 | F | n.a. | n.a. | 8.9 | 2.1 | Yes |
Sass et al.9 | US | 1 | Breast | 55 | F | Breast cancer cells; fibrosis | n.a. | 6.8 | 2.4 | Yes |
Tambe et al.59 | US | 1 | Breast | 71 | F | Breast cancer cells | 76.000 | 0.4 | n.a. | n.a. |
Teke et al.60 | Turkey | 1 | Colon | 50 | M | Adenocarcinoma | n.a. | n.a. | n.a. | Yes |
Uhlmann et al.61 | Germany | 1 | Breast | 59 | F | Breast cancer cells | n.a. | n.a. | n.a. | n.a. |
Wallace et al.62 | US | 1 | Breast | 42 | F | Breast cancer cells | n.a. | n.a. | n.a. | Yes |
Zanazanian et al.63 | US | 1 | Ovary | 43 | F | Ovarian carcinoma | n.a. | n.a. | n.a. | Yes |
Zeina et al.64 | Israel | 1 | Breast | 82 | F | n.a. | n.a. | n.a. | n.a. | Yes |
Aoyagi et al.65 | Japan | 3 | Breast | 65 | F | n.a. | 181.000 | 1.1 | 3.1 | Yes |
65 | F | n.a. | 246.000 | 0.8 | 4.3 | |||||
68 | F | n.a. | 414.000 | 0.8 | 2.2 | |||||
Jeong et al.25 | Korea | 2 | Breast | 53 | F | n.a. | 214.000 | 4.3 | 3.1 | Yes |
25 | F | n.a. | 50.000 | 2.4 | 2.7 | |||||
Nascimento et al.11 | Brazil | 2 | Breast | 62 | F | Breast cancer cells fibrosis | n.a. | 3.2 | n.a. | Yes |
46 | F | Breast cancer cells fibrosis | 27.000 | 7.2 | n.a. | |||||
Gravel et al.5 | Canada | 2 | Breast | 42 | F | Breast cancer cells fibrosis | n.a. | 1.46 | n.a. | Yes |
58 | F | Breast cancer cells fibrosis | n.a. | 27.1 | n.a. | |||||
Qizilbash et al.66 | n.a. | 3 | Breast | 50 | n.a. | n.a. | n.a. | n.a. | n.a. | Yes |
46 | n.a. | n.a. | n.a. | n.a. | n.a. | |||||
70 | n.a. | n.a. | n.a. | n.a. | n.a. | |||||
Vuppalanchi et al.67 | US | 2 | Breast | 47 | F | Breast cancer cells fibrosis | n.a. | 2 | n.a. | Yes |
61 | F | n.a. | n.a. | 2.2 | n.a. | |||||
Geeroms et al.68 | Belgium | 3 | Breast | 56 | F | Breast cancer cells fibrosis | 72.000 | 0.9 | n.a. | Yes |
70 | F | Nodular regenerative hyperplasia | 141.000 | n.a. | n.a. | |||||
79 | F | Breast cancer cells | 250.000 | n.a. | n.a. | |||||
Mizuyama et al.69 | Japan | 2 | Breast | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. |
Shirkoda et al.70 | US | 3 | Breast | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. |
Shinoda et al.23 | Japan | 1 | Stomach | 72 | M | n.a. | n.a. | 1.8 | 3.5 | Yes |
Shijubou et al.71 | Japan | 1 | Lung | 50 | M | Lung adenocarcinoma fibrosis | n.a. | n.a. | n.a. | Yes |
Nakano et al.72 | Japan | 1 | Lung | 64 | M | Lung adenocarcinoma | n.a. | n.a. | 2.7 | Yes |
Basinger et al.73 | US | 1 | Stomach | 71 | M | Gastric adenocarcinoma; fibrosis; nodule | n.a. | n.a. | n.a. | Yes |
